• Evolutionary Perspectives
• 42 min
  1. Antibiotic resistance: a mechanistic overview

  • Dr. Neil Woodford
• 20 min
  2. Mutation

  • Prof. Stephen Gillespie
• 11 min
  3. Fitness in antibiotic resistant bacteria

  • Prof. Stephen Gillespie
• 34 min
  4. Fitness and compensation

  • Dr. Sébastian Gagneux
• 22 min
  5. Antibiotic resistance and the supragenome hypothesis

  • Dr. Bambos Charalambous
• Epidemiology and Clinical Impact
• 37 min
  6. Methicillin resistant S. aureus and other resistances

  • Prof. Mark Enright
• 43 min
  7. Risk factors for antibiotic resistance in Streptococcus pneumoniae

  • Prof. Keith Klugman
• 38 min
  8. Beta-lactamases: clinical impact and epidemiology

  • Prof. Sebastian Amyes
• 49 min
  9. Glycopeptide-resistant enterococci

  • Dr. Neil Woodford
• 33 min
  10. Drug resistant tuberculosis: biology, epidemiology and control

  • Dr. Christopher Dye
• 26 min
  11. Antiretroviral drug resistance

  • Prof. Deenan Pillay
• 49 min
  12. Malaria - changing paradigms

  • Dr. Janet Cox-Singh
• 42 min
  13. Advances in mode of action of antimalarials and resistance mechanisms 1

  • Prof. David Warhurst
• 38 min
  14. Advances in mode of action of antimalarials and resistance mechanisms 2

  • Prof. David Warhurst
• Diagnosis and Surveillance of Resistance
• 29 min
  15. Conventional and automated diagnostic methods

  • Dr. Alan Johnson
• 38 min
  16. National and international surveillance of antibiotic resistance 1

  • Prof. David Livermore
• 50 min
  17. National and international surveillance of antibiotic resistance 2

  • Prof. David Livermore
• 24 min
  18. Innovative approaches to rapid antibiotic resistance testing

  • Dr. Robert Hammond
• Controlling Antibiotic Resistance
• 39 min
  19. Controlling antibiotic resistance in the hospital environment

  • Dr. Ian Eltringham
• 27 min
  20. Controlling antibiotic resistance in the community

  • Dr. Peter Wilson
• 51 min
  21. Public policy to reduce antibiotic resistance

  • Dr. Niels Frimodt-Møller
• The Antibiotic Resistance Future
• 26 min
  22. Overcoming resistance through novel drug targets

  • Prof. Anthony Coates
• 37 min
  23. Medicinal chemistry strategies in combating antibiotic resistance

  • Dr. Geoffrey Coxon
• 36 min
  24. Teixobactin kills pathogens without detectable resistance

  • Prof. Kim Lewis
• Archived Lectures *These may not cover the latest advances in the field
• 48 min
  25. Molecular diagnosis of antibiotic resistance

  • Dr. Tim McHugh
• 36 min
  26. Introduction to malaria

  • Prof. David Warhurst

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Fitness and resistance
3. Assessment of growth rate/fitness
4. Growth formula
5. Bacteria growth experience illustration
6. Comparative method illustration
7. Relative fitness of resistant M. tuberculosis
8. Relative fitness and number of clinical isolates
9. Relative fitness in medium vs. macrophages
10. Other measures of fitness
11. Fit the measure to the specie - Staphylococci
12. Resistance not always results in fitness-deficit (1)
13. Resistance not always results in fitness-deficit (2)
14. Another method for testing fitness
15. Genetic background influence on growth
16. Sequential passage methodology
17. Results of passage for 88 generation
18. In vivo adaptation
19. Spectra of compensated mutants isolated
20. Adaptation occurs readily in humans
21. Genetic basis for resistance and fitness
22. Conclusion

Topics Covered

• Fitness and resistance
• Assessment of growth rate/fitness
• Sequential passage methodology
• In vivo adaptation
• Transmission of strains
• Bacteria rapidly adapt

Links

Series:

• Antibiotic Resistance

Categories:

• Microbiology

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Publication History

• Published on January 13, 2010

Financial Disclosures

• Prof. Stephen Gillespie is in receipt of research grants from MMRC, EDCTP, Global Alliance for TB Drug Development. Professor Gillespie’s involvements in clinical trials are supported by active and placebo drug supplies from Bayer Schering Health Care and Sanofi Aventis, while also providing support with regulatory and drug safety advice. Neither company has a managerial role within the study, however. Professor Gillespie has also provided training to senior staff at Bayer Schering Health Care.